home / stock / ptn / ptn articles
Investors might want to bet on Palatin Technologies, Inc. (AMEX:PTN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change...
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the c...
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, whic...
Palatin Technologies Inc (NASDAQ:PTN) shares are trading lower after the company released results for its PL9643 MELODY-1 pivotal Phase 3 clin...
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the...
Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter f...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...